ACM
NVO

Aljian Capital Management’s Novo Nordisk NVO Stock Holding History

Aljian Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,129
Closed -$210K – 133
2025
Q4 		$210K Sell
4,129
-1,250
-23% -$63.9K 0.04% 117
2025
Q3 		$298K Buy
5,379
+538
+11% +$31.5K 0.06% 107
2025
Q2 		$334K Buy
4,841
+20
+0.4% +$1.36K 0.07% 99
2025
Q1 		$335K Buy
4,821
+30
+0.6% +$2.48K 0.08% 100
2024
Q4 		$412K Buy
4,791
+330
+7% +$35.7K 0.09% 84
2024
Q3 		$531K Buy
+4,461
New +$595K 0.12% 76

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Aljian Capital Management's NVO Position: Q1 2026 in Review

Aljian Capital Management sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 4,129 shares — an estimated $210K sold.

Aljian Capital Management first reported a position in NVO in Q3 2024 and held it in 6 quarters. The position peaked at $531K in Q3 2024. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Aljian Capital Management reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Aljian Capital Management sold 4,129 Novo Nordisk shares in Q1 2026, an estimated $210K.
  • Aljian Capital Management first reported a position in Novo Nordisk in Q3 2024 and held it in 6 quarters.
  • Aljian Capital Management's Novo Nordisk position peaked at $531K in Q3 2024.
  • 1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Aljian Capital Management's 13F filing for Q1 2026, filed 29 Apr 2026.